|Bid||50.17 x 800|
|Ask||50.18 x 1200|
|Day's range||49.87 - 50.85|
|52-week range||44.76 - 54.26|
|Beta (5Y monthly)||0.40|
|PE ratio (TTM)||8.63|
|Forward dividend & yield||1.93 (3.70%)|
|Ex-dividend date||03 May 2021|
|1y target est||63.88|
Sanofi has agreed to acquire U.S. biotech company Translate Bio to gain exposure in the mRNA vaccine space.
U.S. biopharmaceutical company Viatris (NASDAQ: VTRS) and its partner, Indian biopharma Biocon, announced on July 28 that the U.S. Food and Drug Administration (FDA) had approved their biosimilar insulin drug, Semglee, as an "interchangeable biosimilar" -- a direct alternative to Sanofi's (NASDAQ: SNY) blockbuster insulin drug, Lantus. Semglee is the first interchangeable biosimilar insulin product approved by the FDA.
The biotech sector seems like a lucrative investment space as the delta variant of coronavirus continues to spread.